Synageva (GEVA) PT Raised to $124 at Nomura
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/26/2026
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- White House blocks CNN from Air Force One trip, Washington Post reports
- Exclusive-SK Hynix's Solidigm weighs IPO that could value the unit at up to $150 billion, sources say
- Merck and Daiichi Sankyo withdraw lung cancer drug application
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Fox Factory sells Marucci Sports for $225M, cuts debt
Synageva BioPharma (GEVA) PT Raised to $111 at Wedbush
January 7, 2015 3:59 PM ESTWedbush analyst David Nierengarten raised his price target on Outperform-rated Synageva BioPharma (NASDAQ: GEVA) to $111.00 (from $97.00) after the company updated its pipeline and identifies a third clinical candidate.
Nierengarte highlights:
GEVA will advance SBC-105, an ERT in preclinical development for rare calcification... MoreSynageva BioPharma (GEVA) Prices Larger 3M Common Offering at $94.19/Share
January 7, 2015 7:40 AM ESTSynageva BioPharma (NASDAQ: GEVA) announced the pricing of its previously announced underwritten public offering of common stock consisting of 3.0 million shares at $94.19 per share. In connection with this offering, Synageva granted to the underwriters a 30-day option to purchase 450,000 additional shares of common stock.... More
